{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:32:53Z","timestamp":1778754773711,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejradiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejrad.2025.112570","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T07:43:39Z","timestamp":1764056619000},"page":"112570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and efficacy of Yttrium-90 transarterial radioembolization of neuroendocrine liver metastasis \u2013 A retrospective single-institution study"],"prefix":"10.1016","volume":"195","author":[{"given":"Gavin","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena N.","family":"Petre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Marquis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Kesner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Lundi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaya S.","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlasios","family":"Sotirchos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Reidy-Lagunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitya","family":"Raj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etay","family":"Ziv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7880-3565","authenticated-orcid":false,"given":"Erica S.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejrad.2025.112570_b0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112570_b0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaoncol.2019.4568","article-title":"Neuroendocrine tumors-less well known, often misunderstood, and rapidly growing in incidence","volume":"6","author":"Chauhan","year":"2020","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.ejrad.2025.112570_b0015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s11605-018-3862-2","article-title":"The impact of extent of liver resection among patients with neuroendocrine liver metastasis: an international multi-institutional study","volume":"23","author":"Sham","year":"2019","journal-title":"J. Gastrointest. Surg."},{"issue":"17","key":"10.1016\/j.ejrad.2025.112570_b0020","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.2010.33.0688","article-title":"Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression","volume":"29","author":"Panzuto","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ejrad.2025.112570_b0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.ejrad.2025.112570_b0030","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.suc.2020.02.010","article-title":"Neuroendocrine tumors of the pancreatobiliary and gastrointestinal tracts","volume":"100","author":"Bonds","year":"2020","journal-title":"Surg. Clin. North Am."},{"issue":"3","key":"10.1016\/j.ejrad.2025.112570_b0035","doi-asserted-by":"crossref","first-page":"441","DOI":"10.21037\/jgo.2016.02.02","article-title":"Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience","volume":"7","author":"Singla","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"issue":"3","key":"10.1016\/j.ejrad.2025.112570_b0040","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","article-title":"Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients","volume":"31","author":"Kennedy","year":"2008","journal-title":"Am. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejrad.2025.112570_b0045","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00270-011-0248-1","article-title":"Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using Yttrium-90 microspheres","volume":"35","author":"Paprottka","year":"2012","journal-title":"Cardiovasc. Interv. Radiol."},{"issue":"5","key":"10.1016\/j.ejrad.2025.112570_b0050","first-page":"679","article-title":"(90)Y radioembolization in the treatment of neuroendocrine neoplasms: results of an international multicenter retrospective study","volume":"63","author":"Schaarschmidt","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.ejrad.2025.112570_b0055","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/jso.24967","article-title":"Histopathological changes resulting from selective internal radiotherapy (SIRT)","volume":"117","author":"Justinger","year":"2018","journal-title":"J. Surg. Oncol."},{"issue":"7","key":"10.1016\/j.ejrad.2025.112570_b0060","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00270-016-1323-4","article-title":"Lung shunt fraction prior to yttrium-90 radioembolization predicts survival in patients with neuroendocrine liver metastases: single-center prospective analysis","volume":"39","author":"Ludwig","year":"2016","journal-title":"Cardiovasc. Interv. Radiol."},{"issue":"2","key":"10.1016\/j.ejrad.2025.112570_b0065","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clon.2020.12.003","article-title":"Current status and future direction of hepatic radioembolisation","volume":"33","author":"Alsultan","year":"2021","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ejrad.2025.112570_b0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cct.2016.08.001","article-title":"Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization","volume":"50","author":"Fan","year":"2016","journal-title":"Contemp. Clin. Trials"},{"issue":"2","key":"10.1016\/j.ejrad.2025.112570_b0075","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejrad.2025.112570_b0080","unstructured":"Common terminology criteria for adverse events (CTCAE) version 5.0 2017. Common Terminology Criteria for Adverse Events (CTCAE) 2017 [cited 2023 November 29]; 5.0:[Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"issue":"8","key":"10.1016\/j.ejrad.2025.112570_b0085","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00270-017-1703-4","article-title":"Cirse quality assurance document and standards for classification of complications: the cirse classification system","volume":"40","author":"Filippiadis","year":"2017","journal-title":"Cardiovasc. Intervent. Radiol."},{"issue":"13","key":"10.1016\/j.ejrad.2025.112570_b0090","first-page":"19","article-title":"Regression standard errors in clustered samples","volume":"3","author":"Rogers","year":"1994","journal-title":"Stata Tech. Bull. (STB)"},{"issue":"2","key":"10.1016\/j.ejrad.2025.112570_b0095","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.0006-341X.2000.00645.x","article-title":"A note on robust variance estimation for cluster-correlated data","volume":"56","author":"Williams","year":"2000","journal-title":"Biometrics"},{"issue":"43","key":"10.1016\/j.ejrad.2025.112570_b0100","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J. Open Source Softw."},{"key":"10.1016\/j.ejrad.2025.112570_b0105","unstructured":"Sjoberg, D., et al. ggsurvfit: Flexible Time-to-Event Figures. Version 1.0]. Available from: https:\/\/CRAN.R-project.org\/package=ggsurvfit."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112570_b0110","first-page":"570","article-title":"Reproducible summary tables with the gtsummary Package","volume":"13","author":"Sjoberg","year":"2021","journal-title":"R Journal"},{"key":"10.1016\/j.ejrad.2025.112570_b0115","unstructured":"Sjoberg, D. and T. Fei. tidycmprsk: Competing Risks Estimation. 2023; 1.0.0:[Available from: https:\/\/cran.r-project.org\/web\/packages\/tidycmprsk\/index.html."},{"key":"10.1016\/j.ejrad.2025.112570_b0120","unstructured":"Therneau, T.M., et al. A Package for Survival Analysis in R. 2024; 3.7-0:[Available from: https:\/\/cran.r-project.org\/web\/packages\/survival\/index.html."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112570_b0125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.beem.2016.01.004","article-title":"Liver transplantation for the treatment of neuroendocrine liver metastases","volume":"30","author":"Vilchez","year":"2016","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.ejrad.2025.112570_b0130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082249","article-title":"Neuroendocrine tumors: genomics and molecular biomarkers with a focus on metastatic disease","volume":"15","author":"Alexander","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejrad.2025.112570_b0135","unstructured":"Neuroendocrine and Adrenal Tumors. NCCN Clinical Practice Gudelines in Oncology 2025 May 28, 2025 [cited 2025 August 23]; 2.2025:[Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf."},{"issue":"12","key":"10.1016\/j.ejrad.2025.112570_b0140","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1007\/s11864-023-01152-6","article-title":"Liver-directed therapy for neuroendocrine tumor metastases in the era of peptide receptor radionuclide therapy","volume":"24","author":"Rabei","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"issue":"02","key":"10.1016\/j.ejrad.2025.112570_b0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0041-1729755","article-title":"Radioembolization for metastatic neuroendocrine tumors","volume":"05","author":"El-Haddad","year":"2021","journal-title":"Digest. Dis. Intervent."},{"issue":"12","key":"10.1016\/j.ejrad.2025.112570_b0150","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2967\/jnumed.121.263041","article-title":"Radioembolization versus bland or chemoembolization for liver-dominant neuroendocrine tumors: is it an either\/or question?","volume":"62","author":"Strosberg","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112570_b0155","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-018-2782-5","article-title":"Randomized embolization trial for neuroendocrine tumor metastases to the liver (RETNET): study protocol for a randomized controlled trial","volume":"19","author":"Chen","year":"2018","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.ejrad.2025.112570_b0160","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1016\/j.jvir.2025.01.015","article-title":"LBA7 randomized embolization trial for neuroendocrine tumors (RETNET)","volume":"36","author":"Soulen","year":"2025","journal-title":"J. Vasc. Interv. Radiol."},{"key":"10.1016\/j.ejrad.2025.112570_b0165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejrad.2018.01.012","article-title":"Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review","volume":"100","author":"Jia","year":"2018","journal-title":"Eur. J. Radiol."},{"issue":"1","key":"10.1016\/j.ejrad.2025.112570_b0170","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-09302-z","article-title":"Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry","volume":"22","author":"Wong","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejrad.2025.112570_b0175","first-page":"3","article-title":"Selective internal radiation therapy for neuroendocrine liver metastases: efficacy, safety and prognostic factors. A retrospective single institution study","volume":"88","author":"Briol","year":"2025","journal-title":"Acta Gastroenterol. Belg."},{"issue":"7","key":"10.1016\/j.ejrad.2025.112570_b0180","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00259-017-3646-z","article-title":"Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients","volume":"44","author":"Paprottka","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ejrad.2025.112570_b0185","doi-asserted-by":"crossref","unstructured":"Miszczuk M, C.J., Do Minh D, van Breugel JMM, Smolka S, Rexha I, Tegel B, Lin M, Savic LJ, Hong K, Georgiades C, Nezami N., Analysis of tumor burden as a biomarker for patient survival with neuroendocrine tumor liver metastases undergoing intra-arterial therapies: A single-center retrospective analysis. 2022.","DOI":"10.1007\/s00270-022-03209-9"},{"issue":"1","key":"10.1016\/j.ejrad.2025.112570_b0190","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00270-023-03614-8","article-title":"Integrated capecitabine-temozolomide with radioembolization for liver-dominant G2 NETs: long-term outcomes of a single-institution retrospective study","volume":"47","author":"Soulen","year":"2024","journal-title":"Cardiovasc. Intervent. Radiol."},{"issue":"4","key":"10.1016\/j.ejrad.2025.112570_b0195","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s13139-014-0292-2","article-title":"Sequential use of (90)Y microspheres radioembolization and (177)Lu-Dotatate in pluri-metastatic neuroendocrine tumors: a case report","volume":"48","author":"Filippi","year":"2014","journal-title":"Nucl. Med. Mol. Imaging"},{"issue":"11","key":"10.1016\/j.ejrad.2025.112570_b0200","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/RLU.0000000000000935","article-title":"Peptide receptor radionuclide therapy-induced hepatotoxicity in patients with metastatic neuroendocrine tumors","volume":"40","author":"Riff","year":"2015","journal-title":"Clin. Nucl. Med."},{"issue":"11","key":"10.1016\/j.ejrad.2025.112570_b0205","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jvir.2018.05.023","article-title":"DAXX mutation status of embolization-treated neuroendocrine tumors predicts shorter time to hepatic progression","volume":"29","author":"Ziv","year":"2018","journal-title":"J. Vasc. Interv. Radiol."},{"issue":"8","key":"10.1016\/j.ejrad.2025.112570_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084041","article-title":"Pancreatic neuroendocrine neoplasms in multiple endocrine neoplasia type 1","volume":"22","author":"Marini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejrad.2025.112570_b0215","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.35947","article-title":"Post-embolization syndrome following yttrium-90 radiation segmentectomy","author":"Vanani","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ejrad.2025.112570_b0220","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fonc.2014.00198","article-title":"Side effects of yttrium-90 radioembolization","volume":"4","author":"Riaz","year":"2014","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.ejrad.2025.112570_b0225","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000368075","article-title":"Spinal cord ischemia secondary to transcatheter arterial chemoembolization for hepatocellular carcinoma","volume":"8","author":"Bazine","year":"2014","journal-title":"Case Rep. Gastroenterol."},{"issue":"2","key":"10.1016\/j.ejrad.2025.112570_b0230","doi-asserted-by":"crossref","first-page":"404","DOI":"10.13004\/kjnt.2022.18.e65","article-title":"Spinal cord infarction after transarterial chemoembolization for hepatocellular carcinoma","volume":"18","author":"Lee","year":"2022","journal-title":"Korean J. Neurotrauma"},{"issue":"12","key":"10.1016\/j.ejrad.2025.112570_b0235","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jvir.2019.06.003","article-title":"Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis","volume":"30","author":"Currie","year":"2019","journal-title":"J. Vasc. Interv. Radiol."},{"issue":"7","key":"10.1016\/j.ejrad.2025.112570_b0240","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/cncr.23339","article-title":"Liver disease induced by radioembolization of liver tumors","volume":"112","author":"Sangro","year":"2008","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ejrad.2025.112570_b0245","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jvir.2011.06.006","article-title":"Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center","volume":"22","author":"Piana","year":"2011","journal-title":"J. Vasc. Interv. Radiol."},{"issue":"8","key":"10.1016\/j.ejrad.2025.112570_b0250","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2967\/jnumed.124.267774","article-title":"Dose-response relationship in patients with liver metastases from neuroendocrine neoplasms undergoing radioembolization with (90)Y glass microspheres","volume":"65","author":"Watanabe","year":"2024","journal-title":"J. Nucl. Med."}],"container-title":["European Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X25006564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X25006564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:00:05Z","timestamp":1778752805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0720048X25006564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":50,"alternative-id":["S0720048X25006564"],"URL":"https:\/\/doi.org\/10.1016\/j.ejrad.2025.112570","relation":{},"ISSN":["0720-048X"],"issn-type":[{"value":"0720-048X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of Yttrium-90 transarterial radioembolization of neuroendocrine liver metastasis \u2013 A retrospective single-institution study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejrad.2025.112570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112570"}}